CAR T-cell therapy showed encouraging efficacy and good safety in newly diagnosed Ph-positive ALL,” the researchers wrote.

Researchers used FAERS data to understand and identify adverse drug reactions associated with capmatinib intake, newly identifying ototoxicity as a possible reaction.

The average number of industry-funded trials started per month was 135.8 before the IRA was passed and 83.6 after — a 38.4% decrease.

Investigators examined the effect of immunosuppression on poor outcomes among patients with cutaneous squamous cell carcinoma.

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...